Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53 alpha), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53 beta and p53 gamma , comprising exons 1 to 9 beta or 9 gamma , respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53 beta and p53 gamma and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 over expression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

Targeting HAUSP in Both P53 Wildtype and P53-Mutant Tumors.

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Deubiquitination of P53 by HAUSP is an Important Pathway for P53 Stabilization

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Structural Basis of Competitive Recognition of P53 and Mdm2 by Hausp/Usp7: Implications for the Regulation of the P53-Mdm2 Pathway

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

HLA-B-associated Transcript 3 (bat3) Stabilizes and Activates P53 in a HAUSP-dependent Manner

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

Small Molecule Inhibitors of the P53-Mdm2

Roles of HAUSP-mediated p53 regulation in central nervous system development

USP7: Target Validation and Drug Discovery for Cancer Therapy

Inhibition of USP14 Deubiquitinating Activity As a Potential Therapy for Tumors with P53 Deficiency

HAUSP Deubiquitinates and Stabilizes N-Myc in Neuroblastoma

Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy

USP4 Inhibits P53 and NF-κB Through Deubiquitinating and Stabilizing HDAC2

Synthesis and Biological Evaluation of Thiazole Derivatives As Novel USP7 Inhibitors.

Modeling the Etiology of p53-mutated Cancer Cells